Chromocell Therapeutics CorpNYSE American:CHRO
- LAST PRICE1.6000
- TODAY'S CHANGE (%)0.1000 (6.6667%)
- Bid / Lots1.5500/ 16
- Ask / Lots1.7500/ 1
- Open / Previous Close1.4899 / 1.5000
- Day Range
- 52 Week Range
- Volume26,703
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CHRO |
|---|---|---|
| 09:38 ET | 750 | 1.49 |
| 09:39 ET | 416 | 1.5 |
| 09:43 ET | 100 | 1.5 |
| 09:52 ET | 300 | 1.5106 |
| 09:56 ET | 947 | 1.5384 |
| 09:57 ET | 200 | 1.53 |
| 10:19 ET | 726 | 1.5001 |
| 10:32 ET | 100 | 1.5 |
| 10:33 ET | 500 | 1.51 |
| 10:46 ET | 200 | 1.65 |
| 11:06 ET | 467 | 1.73 |
| 12:03 ET | 800 | 1.63 |
| 12:14 ET | 801 | 1.68 |
| 12:18 ET | 401 | 1.68 |
| 12:57 ET | 300 | 1.78 |
| 01:08 ET | 100 | 1.58 |
| 02:06 ET | 450 | 1.56 |
| 02:18 ET | 450 | 1.54 |
| 02:20 ET | 517 | 1.52 |
| 02:27 ET | 100 | 1.54 |
| 02:29 ET | 400 | 1.52 |
| 02:42 ET | 4851 | 1.61 |
| 03:52 ET | 400 | 1.6 |
| 03:54 ET | 100 | 1.6 |
| 03:57 ET | 454 | 1.6 |
| 03:59 ET | 6155 | 1.6 |
Apr 9, 2024
Chromocell Issues Letter to Stockholders from Chief Executive Officer, from 8:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Chromocell Therapeutics Corp | 9.4M | -1.3x | --- |
Aslan Pharmaceuticals Ltd | 9.4M | -0.1x | --- |
Akari Therapeutics PLC | 9.4M | -0.6x | --- |
Cell MedX Corp | 9.5M | -11.0x | --- |
Chemomab Therapeutics Ltd | 9.1M | 0.0x | --- |
Virios Therapeutics Inc | 9.0M | -1.7x | --- |
Company Information
Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The Company's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
Contact Information
- Headquarters
- 685 Us Highway OneNORTH BRUNSWICK, NJ, United States 08902
- Phone
- 917-644-6313
- Fax
- 302-658-3694
Executives
- Chairman of the Board
- Todd Davis
- Chief Executive Officer, Chief Financial Officer, Treasurer, Company Secretary
- Francis Knuettel
- Chief Medical Officer
- Eric Lang
- Independent Director
- Ezra Friedberg
- Independent Director
- Richard Malamut
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.28 |
Book Value | $-1.12 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
